Asia Pacific Immunodiagnostics Market Forecast to 2030

Asia Pacific Immunodiagnostics Market Forecast to 2030 – Regional Analysis – by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Send Enquiry
Item ID: BMIRE00027857 Category: Tags: , ,

$2,100$3,500

Description

The Asia Pacific immunodiagnostics market is expected to grow from US$ 2,409.90 million in 2023 to US$ 4,252.35 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2023 to 2030.

Technological Advancements in Immunodiagnostics Drive Asia Pacific Industrial Robotics Market

The current trend in immunodiagnostics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.

The increasing applications of immunodiagnostics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.

In microfluidics, some immunodiagnostics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.

In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.

Asia Pacific Immunodiagnostics Market Overview

According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020. Almost 80% of deaths among people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and Type II diabetes. According to China Blueprint, immunological diagnosis has exceeded biochemical diagnosis (accounting for 27%), and the in vitro diagnostics (IVD) market has gone mainstream in China. However, compared to developed countries, there is still room for alternative biochemical diagnosis to expand in China’s immunodiagnostics market, as the average ratio of biochemical to immunization diagnosis is about 1:2, according to statistical data from several agencies. As technological innovation advances with the growing need for high-end testing, diagnostics is expected to consolidate its mainstream status.

Furthermore, collaborations between organizations are increasing for developing and producing assays. For instance, in December 2023, Ortho Clinical Diagnostics Trading and Shanghai Medconn Biotechnology signed an agreement as part of a joint venture to develop and manufacture assays for the VITROS immunodiagnostics platform in China. The expertise of Ortho Clinical Diagnostics Trading in developing and designing in vitro diagnostics (IVD) technologies for POC settings, clinical labs, and transfusion medicine will propel the growth of the Asia Pacific immunodiagnostics market in the coming years.

Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Immunodiagnostics Market Segmentation

The Asia Pacific immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Asia Pacific immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered a largest share in the Asia Pacific immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered a largest share in the Asia Pacific immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered a largest share in the Asia Pacific immunodiagnostics market.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China registered a largest share in the Asia Pacific immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific immunodiagnostics market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 8.5% CAGR, the Asia Pacific Immunodiagnostics Market is Speculated to be worth US$ 4,252.35 million by 2030, saysthe research team

According tothe research team Market research, the Asia Pacific immunodiagnostics market was valued at US$ 2,409.90 million in 2023 and is expected to reach US$ 4,252.35 million by 2030, registering a CAGR of 8.5% from 2023 to 2030. Rising focus on R&D investment and expansion by key players and technological advancements in immunodiagnostics are the critical factors attributed to the Asia Pacific immunodiagnostics market expansion.

Research and development (R&D) have been the crucial part of the pharmaceutical business. It enables companies to develop new products with significant medical and commercial potential for various diagnostic applications. Due to the surging prevalence of infectious diseases, companies invest and generate huge revenues for expansion activities. During the COVID-19 pandemic, Thermo Fisher Scientific Inc. witnessed a 48% increase in the sales of its specialty diagnostics segment (sub-segmented into clinical diagnostics, immunodiagnostics, microbiology, transplant diagnostics, and healthcare market channel) in 2020. The segmental revenue of the company further increased in 2021 due to higher demand and sales of immunodiagnostics products used in COVID-19 treatment. Siemens Healthineers announced the investment of over US$ 32 million in its Glasgow Laboratory Diagnostics Manufacturing Facility in Newark, Delaware, in September 2021. The investment extending over 24 months, enabled the company to add over 20 diagnostic tests in Delaware manufacturing capabilities. This initiative boosted the productivity of companies by maintaining stability across their diagnostic supply chains.

The extensive R&D for introducing innovative products opens several opportunities for small players and start-ups. Manufacturers have also made a few key investments in the last few years. Cisco Systems, a global technology leader, invested US$ 225 million to combat the COVID-19 pandemic. This enabled the company to expand significantly and encourage new players to enter the market.

On the contrary, inadequate reimbursement scenario hurdles the growth of Asia Pacific immunodiagnostics market.

Based on product, the Asia Pacific immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.3% share of Asia Pacific immunodiagnostics market in 2023, amassing US$ 1,333.04 million. It is projected to garner US$ 2,325.03 million by 2030 to expand at 8.3% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 45.0% share of Asia Pacific immunodiagnostics market in 2023, amassing US$ 1,084.39 million. It is projected to garner US$ 1,983.05 million by 2030 to expand at 9.0% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.5% share of Asia Pacific immunodiagnostics market in 2023, amassing US$ 1,047.75 million. It is projected to garner US$ 1,816.14 million by 2030 to expand at 8.2% CAGR during 2023–2030.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.2% share of Asia Pacific immunodiagnostics market in 2023. It was assessed at US$ 703.69 million in 2023 and is likely to hit US$ 1,226.80 million by 2030, exhibiting a CAGR of 8.3% during 2023–2030.

Key players operating in the Asia Pacific immunodiagnostics market are Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Immunodiagnostics Market – by Product
1.3.2 Asia Pacific Immunodiagnostics Market – by Clinical Indication
1.3.3 Asia Pacific Immunodiagnostics Market – by End User
1.3.4 Asia Pacific Immunodiagnostics Market – by Country
2. Asia Pacific Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Immunodiagnostics Market – Market Landscape
4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Expert’s Opinion
5. Asia Pacific Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market – Asia Pacific Analysis
6.1 Asia Pacific Immunodiagnostics Market Revenue Forecast and Analysis
7. Asia Pacific Immunodiagnostics Market Analysis – by Product
7.1 Overview
7.2 Asia Pacific Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Immunodiagnostics Market Analysis – Clinical Indication
8.1 Overview
8.2 Asia Pacific Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Immunodiagnostics Market Analysis – End User
9.1 Overview
9.2 Asia Pacific Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Immunodiagnostics Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1.1 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 China: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.1.3.1 China: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4 China: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.1 China: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.2 China: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.5 China: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Japan: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.2.3.1 Japan: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4 Japan: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.1 Japan: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.2 Japan: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.5 Japan: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 India: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.3.3.1 India: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4 India: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.1 India: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.2 India: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.5 India: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.4 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.3 Australia: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.4.3.1 Australia: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4 Australia: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4.1 Australia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4.2 Australia: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.5 Australia: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.5 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.3 South Korea: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.5.3.1 South Korea: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4 South Korea: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4.1 South Korea: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4.2 South Korea: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.5 South Korea: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.6.3.1 Rest of Asia Pacific: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4.1 Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4.2 Rest of Asia Pacific: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.5 Rest of Asia Pacific: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. Asia Pacific Immunodiagnostics Market –Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.2.1 Overview
11.3 Organic Growth Strategies
11.3.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 DiaSorin SpA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Danaher Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 PerkinElmer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 bioMerieux SA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Svar Life Science AB
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About
13.2 Glossary of Terms

LIST OF TABLES

Table 1. China Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 2. China Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 3. China Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 4. China Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 5. China Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 6. China Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Japan Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. India Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. India Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 15. India Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 16. India: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 17. India Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 18. India Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 24. Australia Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 29. South Korea Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 30. South Korea Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 34. Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 35. Rest of Asia Pacific Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. Recent Inorganic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 38. Recent Organic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 39. Glossary of Terms, Asia Pacific Immunodiagnostics Market

LIST OF FIGURES

Figure 1. Asia Pacific Immunodiagnostics Market Segmentation
Figure 2. Asia Pacific Immunodiagnostics Market, by Country
Figure 3. Asia Pacific Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in Asia Pacific Immunodiagnostics Market
Figure 5. India Expected to Show Remarkable Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Asia Pacific Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. Asia Pacific Immunodiagnostics Market – Revenue Forecast and Analysis – 2021–2030
Figure 10. Asia Pacific Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA):Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
Figure 20. Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. Asia Pacific Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
Figure 42. Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. Asia Pacific: Immunodiagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 48. Asia Pacific: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. China: Immunodiagnostics market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Japan: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. India: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Australia: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 53. South Korea: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 54. Rest of Asia Pacific: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – Asia Pacific Immunodiagnostics Market

– Abbott Laboratories
– bioMerieux SA
– Danaher Corp
– DiaSorin SpA
– F. Hoffmann-La Roche Ltd
– PerkinElmer Inc
– Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
– Siemens Healthcare GmbH
– Svar Life Science AB
– Thermo Fisher Scientific Inc

Reviews

There are no reviews yet.

Be the first to review “Asia Pacific Immunodiagnostics Market Forecast to 2030”